Selling pressure pushes Pfizer stock lower in today's trading

Traders Union
All News
Financial News
Pfizer slides 2.12% today to $25.65

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Sholanke Dele

01.06.2026

Selling pressure pushes Pfizer stock lower in today's trading — Pfizer slides 2.12% today to $25.65

Pfizer Inc. (PFE) is trading at $25.65, down 2.12% on the day. The stock sits just below its 20-day moving average at $25.98 and well under the 50-day at $26.73, but remains slightly above the 200-day moving average at $25.83, reflecting ongoing short- and medium-term selling pressure while holding longer-term support.

PFE price prediction

24H -0.58%

$25.62

48H -0.74%

$25.58

7D 0.5%

$25.9

1M -3.49%

$24.87

3M -3.41%

$24.89

6M 1.44%

$26.14

12M 8.34%

$27.92

Detailed

Current price: $ 25.77 0.4100 1.62%

Real-time Data 12:48

Daily range 25.65

25.91

Weekly range 25.27

26.22

Highlights

Pfizer formed a global partnership with Innovent Biologics worth up to $10.5 billion to advance oncology drug development and commercialization.
Detailed Phase 3 study results for Talzenna and Xtandi combinations in gene-mutated metastatic prostate cancer underscore Pfizer's progress in targeted therapies.
Pfizer trades under notable short- and medium-term pressure, with a near-term range of $25.21–25.94 and a sideways bias expected.

Dividends hold steady as oncology deal fails to lift sentiment

Pfizer entered into a global partnership with Innovent Biologics valued at up to $10.5 billion to co-develop and commercialize oncology medicines, including antibody-drug conjugates and multi-specific antibodies. The company also reported detailed Phase 3 Talapro-3 study results showing outcomes for the Talzenna and Xtandi combination in gene-mutated metastatic castration-sensitive prostate cancer. Pfizer maintained a dividend yield of about 6.5% with a long-standing record of consistent quarterly payments, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees continued selling pressure on Pfizer, with price currently weak against short- and medium-term technical levels. He notes persistent downside bias in momentum, as indicated by MACD and price action below key moving averages. Dividend sustainability provides some fundamental support, but he remains skeptical that recent news can offset market caution right now. Technical indicators raise red flags, with mixed signals and low conviction from buyers. "I see an uneasy balance — until bulls reclaim $26.39, sellers remain in firm control and downside risks persist."

Viktoras Karapetjanc, expert at Traders Union, believes Pfizer’s robust partnership with Innovent and strong dividend track record reinforce its bullish long-term structure. He sees these fundamentals supporting recovery despite near-term volatility. Most weekly signals point to further upside, and the partnership news boosts sentiment for growth in oncology. "With solid fundamentals and a 75% likelihood for gains, I expect Pfizer to push toward $25.94 and offer fresh opportunities for active investors."

Mixed momentum and resistance cap gains amid intraday pressure

Pfizer is trading just below its 20-day moving average at $25.98 and well under the 50-day moving average of $26.73, but remains slightly above the 200-day moving average at $25.83, highlighting pronounced short- and medium-term pressure from sellers, with longer-term support still intact. The nearest dynamic resistance is set by the Ichimoku Kijun at $26.39. Momentum signals are mixed: the MACD indicates a strong sell bias on the daily chart, while the Average Directional Index (ADX) is neutral, suggesting weak trend strength. Relative Strength Index (RSI) sits at 50.12, and the Stochastic RSI signals overbought, pointing to the risk of a cooling period. Commodity Channel Index (CCI) remains neutral. Bull/Bear Power (BBP) is positive at 0.21, meaning buyers have a modest edge in intraday action, though overbought conditions are present. The stock is down 2.12% on the day with a $0.10 downside gap open. Its current price is near the low end of the session’s $25.93 — 26.22 range, and intraday volatility stands at 1.12%. The tone remains pressured after the open, with daily losses in line with weak momentum.

Earlier, analysts noted that Pfizer shares were consolidating under persistent selling pressure but maintained underlying long-term support. The latest partnership developments and mixed technical momentum further emphasize the importance of monitoring the $25.21 support level, as a decisive break from the current stability could trigger a notable shift in directional risk.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.